Amgen vs Canon: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Amgen and Canon side by side

1. 1933Canon

   Precision Optical Instruments Laboratory opens

   Goro Yoshida, Saburo Uchida and Takeo Maeda open a camera laboratory in a Roppongi apartment in Tokyo to build a Japanese 35mm camera that could rival the Leica.

2. 1934Canon

   Kwanon prototype

   Yoshida builds the Kwanon, Japan's first 35mm focal-plane-shutter camera prototype, named after the Buddhist goddess of mercy. It never goes on sale.

3. 1936Canon

   Hansa Canon goes on sale

   The lab's first commercial camera, the Hansa Canon, uses a Nikkor lens and rangefinder supplied by Nippon Kogaku, the predecessor of Nikon. The 'Canon' trademark had been filed in 1935.

4. 1937Canon

   Precision Optical Industry incorporated

   The business is incorporated on August 10, 1937 as Precision Optical Industry, Co., Ltd. Takeshi Mitarai becomes president in 1942.

5. 1949Canon

   Tokyo Stock Exchange listing

   Canon Camera Co. (renamed in 1947) lists on the Tokyo Stock Exchange when postwar trading resumes, and opens a New York branch in 1955.

6. 1964Canon

   Canola 130 calculator

   Canon moves beyond cameras with the Canola 130 desktop electronic calculator, followed in 1970 by Japan's first plain-paper copier, the NP-1100, and its first semiconductor lithography tool, the PPC-1.

7. 1969Canon

   Renamed Canon Inc.

   Canon Camera Co. changes its name to Canon Inc. to reflect a product range that now spans business machines as well as cameras.

8. 1980Amgen

   Applied Molecular Genetics is incorporated

   Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.

9. 1983Amgen

   Nasdaq listing and the erythropoietin clone

   Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.

10. 1984Amgen

    Kirin-Amgen joint venture formed

    Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.

11. 1985Amgen

    G-CSF cloned, leading to Neupogen

    While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.

12. 1987Canon

    EOS system launches

    Canon launches the EOS 650 and the all-electronic EF lens mount, the base of its autofocus SLR and later digital SLR lines.

13. 1989Amgen

    FDA approves Epogen

    The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.

14. 1991Amgen

    Neupogen approved, giving Amgen a second franchise

    The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.

15. 1991Amgen

    Amgen wins the erythropoietin patent fight

    On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.

16. 1995Canon

    Fujio Mitarai becomes president

    Fujio Mitarai takes over as president, exits personal computers and other loss-making lines, and in 1996 starts the Excellent Global Corporation Plan.

17. 2001Amgen

    FDA approves Aranesp, the longer-acting EPO

    Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.

18. 2002Amgen

    US$16 billion Immunex acquisition brings Enbrel in-house

    Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.

19. 2003Canon

    Start of No. 1 camera share run

    Canon takes the No. 1 share of the global interchangeable-lens digital camera market, a position it has held every year through 2025.

20. 2010Amgen

    Prolia and XGEVA create the bone health franchise

    The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.

21. 2016Canon

    Toshiba Medical acquisition

    Canon completes the ¥665.5 billion (about $5.9 billion) purchase of Toshiba Medical Systems in December 2016, later renamed Canon Medical Systems.

22. 2018Canon

    EOS R mirrorless system

    Canon launches the full-frame EOS R mirrorless system and RF lens mount.

23. 2019Amgen

    US$13.4 billion purchase of Otezla from Celgene

    Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.

24. 2020Amgen

    Amgen joins the Dow Jones Industrial Average

    Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.

25. 2023Amgen

    US$27.8 billion Horizon Therapeutics acquisition closes

    Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.

26. 2023Canon

    Nanoimprint lithography launch

    Canon releases the FPA-1200NZ2C nanoimprint lithography system in October 2023, able to pattern 14 nm lines, and delists its ADRs from the New York Stock Exchange in March.

27. 2024Amgen

    Imdelltra becomes the first T-cell engager for small cell lung cancer

    The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.

28. 2024Canon

    First NIL shipment and medical impairment

    Canon ships its first nanoimprint system to the Texas Institute for Electronics on September 26, 2024, and books a ~$1.11 billion (¥165.1 billion) goodwill impairment on its medical business for the year.

29. 2025Amgen

    VESALIUS-CV extends the Repatha case to primary prevention

    In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.

30. 2025Canon

    Record net sales of ~$31 billion (¥4,624.7 billion)

    Canon reports record 2025 net sales of ~$31 billion (¥4,624.7 billion) and net income attributable to Canon Inc. of ~$2.23 billion (¥332.1 billion).

31. 2026Amgen

    Medicare price setting reaches Enbrel and Otezla

    Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.

32. 2026Canon

    Phase VII plan and new president

    Canon unveils its 2026-2030 Phase VII plan, merges Canon Medical's operations into Canon Inc. on April 1, and appoints Kazuto Ogawa President and COO on March 27 while Fujio Mitarai stays Chairman and CEO.

Acquisitions

Questions about Amgen vs Canon